LifeVantage initiated with a Buy at Lake Street

Lake Street analyst Brooks O’Neil initiated coverage of LifeVantage (LFVN) with a Buy rating and $26 price target The company’s products activate physical wellness by using science-based formulas that unlock genes to restore optimal cellular function, says the analyst, who expects rapid growth of the MindBody GLP-1 System that targets a demographic looking for a natural approach to the weight loss benefits of GLP-1s to drive the company’s results this quarter and going forward. While “only” modeling 2% revenue growth in FY25, the firm expects EPS growth of 196% and think shares are “attractively valued,” the analyst tells investors.